



March 18, 2019

Press release

CMIC CMO Co., Ltd.
Accu-Break Pharmaceuticals, Inc.

CMIC and ABP have formed a business alliance
on a new flexible dosing tablet technology in Japan

CMIC CMO Co., Ltd. (Head Office: Minato-ku, Tokyo, Representative Director & CEO: Makoto Matsukawa, hereinafter "CMIC CMO") and Accu-Break Pharmaceuticals, Inc. (Head Office: Hollywood, Florida, President: Robert I. Goldfarb, hereinafter "ABP") announced today that the two companies have formed a business alliance. CMIC CMO will be the exclusive agent in Japan for ABP's flexible dosing tablet technology (hereinafter "Accu-Break Tablets"). CMIC CMO has started drug formulation and manufacturing using this technology for investigational and commercial products.

Accu-Break Tablets are bi-layer tablets with the unique technique in which the top layer contains the active pharmaceutical ingredient and the second layer is inert. The tablet is scored and may be accurately broken into precise smaller doses. This technology is suitable for the development of pharmaceutical drugs, especially narrow therapeutic index drugs, that need different dosing by the individual patient. By applying this technology, it is possible to design and manufacture tablets allowing flexible, precise and easier dosing adjustment for pediatric or geriatric patient needs.

This exclusive alliance enables CMIC CMO to deploy ABP's technologies to Japanese pharmaceutical companies. CMIC CMO already has manufacturing facilities experienced with developing and manufacturing the Accu-Break Tablets. CMIC CMO will actively provide formulation development, contract manufacturing services with Accu-Break technology for investigational products and commercial products in the future.

“CMIC Group is Japan’s leading CRO and CMIC CMO is one of the top Contract Development and Manufacturing Organization (CDMO) in Japan with end to end solutions to help pharmaceutical customers to accelerate their new drug development to market” Commented by Makoto Matsukawa, CEO of CMIC CMO. “By proposing new technologies to Japanese clients, CMIC CMO and ABP will respond to the needs of the patients and pharmacists to provide an easy and flexible dosing tablet format, help to promote appropriate drug therapy, and contribute to the advancement of personalized medicine.”

“We are very pleased to collaborate with CMIC CMO to provide flexible and accurate dosing products to serve the Japanese pharmaceutical marketplace. We look forward to entering into agreements with pharmaceutical companies in Japan to assist CMIC CMO in the advancement of personalized medicine” stated Robert I. Goldfarb, President of ABP. “Accu-Break formatted tablets are particularly useful for medications that require frequent and accurate dose adjustments such as those commonly used in cardiology, central nervous system disorders, pain management and diabetes.”

Feature of Accu-Break Tablets




Image of dividing



*Tablets not to scale

*Pre-divided into smaller doses

About CMIC Group

CMIC Group started business in 1992 as the first CRO in Japan, and the company today provides comprehensive support services for the development, manufacturing, sales, and marketing of pharmaceutical products. Also, the company operates to respond to diversifying needs by managing the Healthcare Business sector and developing and selling diagnostic pharmaceuticals and orphan drugs. CMIC Group has developed a unique business model called Pharmaceutical Value Creator (PVC) based on its abundant accumulated experience and knowledge as a CRO pioneer. CMIC Group utilizes the PVC to create new value in the healthcare field.

For more information, visit CMIC Group's website: <https://www.cmicgroup.com/e/>

About Accu-Break Pharmaceuticals, Inc.

ABP is a privately-held corporation based in Hollywood, Florida. ABP is a technology licensing and product development company that has invented, developed and patented a suite of novel Accu-Break technologies that enable pharmaceutical tablets to be made that can be subdivided by hand into accurate partial doses with the intent of making it easier and safer for patients to adjust their dose. ABP currently has 44 patents issued worldwide. For more information please visit www.accubreak.com

Inquiries

CMIC Holdings Co., Ltd. Corporate Communications Division, PR Group

TEL : 03-6779-8200 / e-mail: pr@cmic.co.jp